Sun Sets Up For PD-L1 Play With Checkpoint Acquisition
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.